Table 1.

Demographic characteristics and vaccination status of all study patients, and those with and without severe COVID-19

	All patients with SLE with COVID-19	Severe COVID-19	No severe COVID-19	P value
	N=2890	N=500	N=2390
Age,* mean (SD)	45.9 (12.1)	48.6 (13.2)	45.3 (11.8)	<0.001
Age, N (%)
18–34	542 (18.8%)	90 (18.0%)	452 (18.9%)	<0.001
35–44	724 (25.1%)	88 (17.6%)	636 (26.6%)
45–54	876 (30.3%)	142 (28.4%)	734 (30.7%)
55–64	645 (22.3%)	143 (28.6%)	502 (21.0%)
65–74	63 (2.2%)	23 (4.6%)	40 (1.7%)
75+	40 (1.4%)	14 (2.8%)	26 (1.1%)
Sex, N (%)
Male	208 (7.2%)	60 (12.0%)	148 (6.2%)	<0.001
Female	2682 (92.8%)	440 (88.0%)	2242 (93.8%)
Payer, N, (%)
Commercial	1974 (68.3%)	243 (48.6%)	1731 (72.4%)	<0.001
Medicare	93 (3.2%)	31 (6.2%)	62 (2.6%)
Medicaid	823 (28.5%)	226 (45.2%)	597 (25.0%)
Urban residence, N (%)	2459 (85.1%)	422 (84.4%)	2037 (85.2%)	0.636
US region,† N (%)
Northeast	381 (18.4%)	47 (17.2%)	334 (18.6%)	0.179
Midwest	353 (17.1%)	61 (22.3%)	292 (16.3%)
South	1137 (55.0%)	140 (51.1%)	997 (55.6%)
West/unknown	196 (9.4%)	26 (9.5%)	170 (9.5%)
Race/ethnicity,‡ N (%)
White	272 (33.0%)	51 (22.6%)	221 (37.0%)	0.001
Black	360 (43.7%)	121 (53.5%)	239 (40.0%)
Hispanic	68 (8.3%)	21 (9.3%)	47 (7.9%)
Other/unknown	123 (14.9%)	33 (14.6%)	90 (15.1%)
Evidence of vaccination,§ N (%)
Yes	1016 (35.2%)	128 (25.6%)	888 (37.2%)	<0.001
No	1874 (64.8%)	372 (74.4%)	1502 (62.8%)

*All demographic characteristics assessed on 1 April 2020.

†Region available for patients in the Commercial/Medicare database.

‡Race/ethnicity available for patients in the Medicaid database.

§Evidence of vaccination assessed during patients’ full variable-length follow-up period (1 April 2020 to earliest of death, end of database enrolment, 31 December 2021 (Commercial/Medicare), or 30 June 2021 (Medicaid)).

SLE, systemic lupus erythematosus.